9MW-2921
- Generic Name
- 9MW-2921
Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 261
- Registration Number
- NCT05990452
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Centel, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath